Arthritis Rheumatoid Arthritis What Is Rheumatoid Lung Disease? By Carol Eustice Carol Eustice Facebook Carol Eustice is a writer covering arthritis and chronic illness, who herself has been diagnosed with both rheumatoid arthritis and osteoarthritis. Learn about our editorial process Updated on April 25, 2022 Medically reviewed by Marissa Sansone, MD Medically reviewed by Marissa Sansone, MD LinkedIn Marissa Sansone, MD, is a board-certified doctor of internal medicine and a current fellow in rheumatology at Yale University. She actively teaches rheumatology to medical residents and students, and peer-reviews abstracts in the journal Rheumatology. Learn about our Medical Expert Board Print Table of Contents View All Table of Contents Types Symptoms Causes Diagnosis Treatment Prognosis The group of pulmonary issues collectively defined as rheumatoid lung disease are, as the name suggests, the result of rheumatoid arthritis (RA). Lung damage is common in RA, with more than half of patients having some abnormal lung function. About one in 10 will develop rheumatoid lung disease, which can involve airway blockage, fluid in the chest, lung scarring, and other concerns. Rheumatoid lung disease worsens with time and the lung damage it causes is irreversible, so addressing the condition's symptoms and slowing its progression are critical. Verywell / Theresa Chiechi Types of Rheumatoid Lung Disease The most common manifestation of pulmonary disease in rheumatoid arthritis is interstitial lung disease (ILD), a condition that causes inflammation and scarring (fibrosis) of the lungs. Once lung tissue scars, it no longer functions. The most frequent forms of interstitial lung disease are usually interstitial pneumonia and nonspecific interstitial pneumonia. Another presentation combines pulmonary fibrosis and emphysema. Rheumatoid Lung Disease Symptoms Typical RA symptoms include pain, swelling, and stiffness in the joints. Rheumatoid lung disease has specific additional symptoms that include: Shortness of breath (the most common symptom) Cough Chest pain Fever Crackle sounds when listening to lungs with a stethoscope; decreased breath sounds or normal breath sounds are also possible Rheumatoid lung disease may not present with symptoms until the condition has advanced. That's why it's imperative to see a doctor once they begin. The thoracic and pulmonary abnormalities associated with rheumatoid lung disease include: Pulmonary hypertension, high blood pressure in the lungs' blood vessels Pulmonary fibrosis, scarring of lung tissue Pleural effusion, or "water on the lungs" Pleural thickening, scarring of the lungs' lining Necrobiotic nodules, abnormal lumps within the lung Bronchiectasis, thickening of the bronchial walls Bronchiolitis obliterans, inflammatory obstruction of the bronchioles, the lungs' tiniest airways Bronchiolitis obliterans organizing pneumonia, a separate type of disease than ILD Causes The inflammation and scarring in rheumatoid lung disease comes from the body's immune system attacking the lungs, just as it is attacking the joints in RA itself. Other risk factors: Severe RA: The more active your RA, the greater your chances of developing lung problems.Smoking, which is also a known risk factor of rheumatoid arthritisAge: People diagnosed with RA after age 60 have a higher chance of developing lung disease.Sex: Men have a two- to three-times higher risk of rheumatoid lung disease than women. It also has been suggested that rheumatoid arthritis medications may possibly lead to drug-induced interstitial lung disease in some cases. Methotrexate is the gold standard treatment for rheumatoid arthritis. However, methotrexate has also been suggested as a causative agent in interstitial lung disease. Researchers evaluated the relative risk of pulmonary disease among rheumatoid arthritis patients who were treated with methotrexate. A study concluded there is a small but significant increase in the risk of lung disease in rheumatoid arthritis patients treated with methotrexate compared with other disease-modifying anti-rheumatic drugs (DMARDs) and biologic drugs. For RA patients with no inhibited lung function, the benefits of methotrexate outweigh the risks. But the American College of Rheumatology does not recommend methotrexate for RA patients who already have ILD. Another study evaluated the relative risk of pulmonary disease among rheumatoid arthritis patients treated with Arava (leflunomide). No evidence of increased respiratory adverse events was found in randomized, controlled trials of rheumatoid arthritis patients treated with leflunomide. How Rheumatoid Arthritis Affects Each Part of the Body Diagnosis RA combined with ILD symptoms are enough for a doctor to begin diagnostic testing, but it's critical for patients to seek help as early as possible. Advancements in computer-assisted image analysis have made it possible to diagnose rheumatoid lung disease earlier and treat it aggressively as a disease of the immune system. Also, certain blood tests may help reveal ILD. Research has shown that the increased presence of a series of blood biomarkers (matrix metalloproteinase 7, pulmonary and activation-regulated chemokine, and surfactant protein D) in RA patients may help indicate ILD. Other procedures used to help diagnose the condition include: Physical examination (listening to lungs) Lung function tests Chest X-rays Computed tomography (CT) scan of the chest Echocardiogram Thoracentesis Bronchoscopy Treatment Treatment for rheumatoid lung disease focuses on slowing the condition's progression, reducing symptoms, and improving quality of life. The following treatments may be effective to those ends: More aggressive RA treatment to help reduce symptoms Corticosteroids and immunosuppressants to combat inflammation Oxygen therapy to aid lung function and increase blood oxygen levels Pulmonary rehabilitation: Education and exercises designed to improve lung function and endurance People with the most severe cases of rheumatoid lung disease may be recommended for lung transplants. Prognosis While it is possible to have good quality of life with rheumatoid lung disease, it is a serious condition that shortens RA patients' lifespans. Early and effective treatment is critical. Patients with untreated ILD have a median survival rate of only three years. For patients with ongoing consistent treatment, the disease may stabilize or slow its progression. In one five-year study, healthcare use and costs were mostly stable over time. In that group, hospitalization rates for the condition (including ER visits) were 14% to 20% each year. The median survival rate in that group was 7.8 years post-diagnosis. A Word From Verywell It's important for all rheumatoid arthritis patients to be vigilant for signs of lung damage, particularly those in higher risk groups like men, older patients, and those with severe RA symptoms. Early detection and proper management of rheumatoid lung disease will help determine quality and length of life going forward. Complications of Rheumatoid Arthritis 13 Sources Verywell Health uses only high-quality sources, including peer-reviewed studies, to support the facts within our articles. Read our editorial process to learn more about how we fact-check and keep our content accurate, reliable, and trustworthy. Raimundo K, Solomon JJ, Olson AL, et al. Rheumatoid arthritis-interstitial lung disease in the United States: Prevalence, incidence, and healthcare costs and mortality. J Rheumatol. 2019;46(4):360-9. doi:10.3899/jrheum.171315 Arthritis Foundation. What you need to know about RA and lung disease. American Lung Association. Interstitial lung disease (ILD). Iqbal K, Kelly C. Treatment of rheumatoid arthritis-associated interstitial lung disease: a perspective review. Ther Adv Musculoskelet Dis. 2015;7(6):247–67. doi:10.1177/1759720X15612250 Yunt ZX, Solomon JJ. Lung disease in rheumatoid arthritis. Rheum Dis Clin North Am. 2015;41(2):225-36. doi:10.1016/j.rdc.2014.12.004 Chansakul T, Dellaripa PF, Doyle TJ, Madan R. Intra-thoracic rheumatoid arthritis: Imaging spectrum of typical findings and treatment related complications. Eur J Radiol. 2015;84(10):1981-91. doi:10.1016/j.ejrad.2015.07.008 Yanagisawa S, Inoue C, Ichinose M. Necrobiotic pulmonary nodules of rheumatoid arthritis. Am J Med Sci. 2017;354(3):329. doi:10.1016/j.amjms.2017.02.007 Epler GR. Bronchiolitis obliterans organizing pneumonia. Arch Intern Med. 2001;161(2):158–64. doi:10.1001/archinte.161.2.158 Hagmeyer L, Randerath W. Smoking-related interstitial lung disease. Dtsch Arztebl Int. 2015;112(4):43-50. doi:10.3238/arztebl.2015.0043 Conway R, Low C, Coughlan RJ, O'Donnell MJ, Carey JJ. Methotrexate and lung disease in rheumatoid arthritis: a meta-analysis of randomized controlled trials. Arthritis Rheumatol. 2014;66(4):803-12. doi:10.1002/art.38322 Conway R, Low C, Coughlan RJ, O'Donnell MJ, Carey JJ. Leflunomide use and risk of lung disease in rheumatoid arthritis: A systematic literature review and metaanalysis of randomized controlled trials. J Rheumatol. 2016;43(5):855-60. doi:10.3899/jrheum.150674 Doyle TJ, Patel AS, Hatabu H, et al. Detection of rheumatoid arthritis-interstitial lung disease is enhanced by serum biomarkers. Am J Respir Crit Care Med. 2015;191(12):1403-12. doi:10.1164/rccm.201411-1950OC American Lung Association. The basics of pulmonary rehabilitation. Additional Reading Shaw M, Collins BF, Ho LA, Raghu G. Rheumatoid arthritis-associated lung disease. Eur Respir Rev. 2015;24(135):1-16. doi:10.1183/09059180.00008014 By Carol Eustice Carol Eustice is a writer covering arthritis and chronic illness, who herself has been diagnosed with both rheumatoid arthritis and osteoarthritis. See Our Editorial Process Meet Our Medical Expert Board Share Feedback Was this page helpful? Thanks for your feedback! What is your feedback? Other Helpful Report an Error Submit